A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy but it has severe side-effects. HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. In this retrospective report, we had genotyped HLA-B*5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications. We found 30 carriers of HLA-B*5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B*5801 positive and negative groups. The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated the HLA-B*5801 screening had significant cost benefit for clinical management. HLA-B*5801 allele should be screened in all patients with hyperuiciemia and gout in the Chinese population.
Date Issued
2018-05-01
Date Acceptance
2018-03-13
Citation
Pharmacogenetics and Genomics, 2018, 28 (5), pp.117-124
ISSN
1744-6872
Publisher
Lippincott, Williams & Wilkins
Start Page
117
End Page
124
Journal / Book Title
Pharmacogenetics and Genomics
Volume
28
Issue
5
Copyright Statement
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Subjects
0604 Genetics
1115 Pharmacology And Pharmaceutical Sciences
Pharmacology & Pharmacy
Publication Status
Published